Introduction
In my last article, I outlined the broader investment opportunity in Krystal Biotech (KRYS), a unique gene therapy company focused on dermatological conditions. In that article, I gave a surface level overview of their STAR-D (Skin TARgeted Delivery) gene therapy platform and the company's commercial opportunity in DEB. This article will serve as a "deep dive" piece where I explain, in detail, why I have such high conviction in this investment despite its early stage. I'll be reviewing the science behind KB103 in detail, and why this investment opportunity may be overlooked